Potent Quinoxaline‐Based Inhibitors of PDGF Receptor Tyrosine Kinase Activity. Part 2. The Synthesis and Biological Activities of RPR127963 an Orally Bioavailable Inhibitor.

Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors

Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 1.3K citations

Medicine, Oncology, Pharmacology +15

Clinical management of gastrointestinal stromal tumors: Before and after STI-571

Ronald P. DeMatteo, Michael C. Heinrich, Wael El‐Rifai et al. · Human Pathology · 2002 · 637 citations

Medicine, Oncology, Surgery +10

Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor

Barbara Hanney, Alfred P. Spada, Glenda E. Bilder et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 152 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Potent Quinoxaline‐Based Inhibitors of PDGF Receptor Tyrosine Kinase Activity. Part 2. The Synthesis and Biological Activities of RPR127963 an Orally Bioavailable Inhibitor.

Wei He, et al. et al. · ChemInform · 2003 · 145 citations

Medicine, Medicinal Chemistry, Pharmacology +13

Restenosis Following Angioplasty in the Swine Coronary Artery Is Inhibited By an Orally Active PDGF-Receptor Tyrosine Kinase Inhibitor, RPR101511A

Glenda E. Bilder, Tara Wentz, Robert J. Leadley et al. · Circulation · 1999 · 88 citations

Medicine, Cardiology, Pharmacology +15